Premier Perspectives The blog for insider insights in clinical development Clinical Research: Phase 1 - Phase 4 5 Key Takeaways: Insights on Alternative Designs to the Traditional 3+3 Design in Phase 1 Dose Escalation Studies By Abie Ekangaki April 8, 2021 Featured Posts Clinical ResearchPhase 1 - Phase 4 Considerations for Applying Adaptive Design Approaches to Early Oncology Studies By Abie Ekangaki August 20, 2020 Clinical ResearchPhase 1 - Phase 4 Minimizing Early-Stage Oncology Failures with Adaptive Design Approaches By Abie Ekangaki August 5, 2020 Recent Posts By expertise area All expertise areas Digital TherapeuticsAnalgesiaDermatologyMedical DeviceNeuroscienceOncology & HematologyPediatricsRare DiseaseOtherCOVID-19Cell & Gene TherapyWomen's HealthDiagnosticsReal-World & Late PhaseCareers By functional area All functional areas Clinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development COVID-19 Statistical Considerations for FDA COVID-19 Guidance By Abie Ekangaki March 27, 2020 Clinical ResearchPhase 1 - Phase 4 Leadership Development and Becoming a More Effective Change-maker By Abie Ekangaki April 26, 2019 Study Design 6 Early Phase Dose-Finding Trial Designs for Oncology Therapeutics By Abie Ekangaki December 5, 2017 Clinical ResearchPhase 1 - Phase 4 Where Do We Start?: A Look at Dosing in Phase 1 Trials By Abie Ekangaki November 29, 2017 Consulting Adaptive Design Strategies in Rare Oncology By Abie Ekangaki March 9, 2017 × ALSO OF INTERESTPremier Research Vice President, Statistical...
